Chengdu Pioneer (688222.SH) released semi-annual results, with net profit of 80.68 million yuan to mother, an increase of 61.21% over the previous year

According to Zhitong Finance App News, Chengdu Pioneer (688222.SH) disclosed the 2026 semi-annual report. During the reporting period, the company achieved operating income of 346 million yuan, an increase of 52.41%; net profit to mother of 80.68 million yuan, an increase of 61.21% year on year; after deducting non-net profit of 76.98 million yuan, an increase of 42.80% year on year; basic earnings per share were 0.20 yuan.

DEL (including the design, synthesis, screening and expanded application of DEL libraries) maintained strong growth during the reporting period as the company's cornerstone business, and maintained a high gross profit margin. At the same time, the company continued to deliver milestone revenue corresponding to customer projects during the reporting period, which brought about an overall increase in profits; at the same time, the British subsidiary further consolidated the steady development of the FBDD/SBDD platform (drug discovery technology based on molecular fragments and 3D structural information). While the revenue of the main business segments achieved steady growth, it also achieved milestone revenue for some corresponding projects.

The OBT sector (drug development platform based on oligonucleotides) benefited from the overall activity of the nucleic acid drug market. The company's business in upstream nucleoside monomer synthesis and sequence design, differentiated development of midstream delivery technology, and downstream CMC services grew during the reporting period. At the same time, revenue from small-nucleic acid one-stop projects also achieved year-on-year growth, which jointly drove a significant increase in the overall revenue of the sector; the TP (TP Proximate Induction Drug Related Technology Platform) sector began actively exploring the development paths of various proximate inducing drug molecules during the reporting period. The agreed deliverables gradually realized the transformation to a one-stop R&D project commercialization model.